NASDAQ · IBB
Financial Services · Asset Management
$202.93
Up+$0.29 (+0.14%)
Updated Sep 12, 2026, 1:26 PM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IBB closed at $202.93 after 20 trading sessions, up 2.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $203.94 | $205.31 | $202.75 | $202.93 | 2.29M |
| Sep 10, 2026 | $203.59 | $204.66 | $201.924 | $202.64 | 1.89M |
| Sep 9, 2026 | $206.57 | $207.85 | $205.2001 | $205.49 | 1.12M |
| Sep 8, 2026 | $209.04 | $209.41 | $205.23 | $207.33 | 1.8M |
| Sep 4, 2026 | $211.58 | $213.225 | $211.1773 | $211.92 | 710.16K |
| Sep 3, 2026 | $214.70 | $214.94 | $211.49 | $213.81 | 1.61M |
| Sep 2, 2026 | $211.935 | $215.31 | $210.77 | $213.80 | 1.63M |
| Sep 1, 2026 | $208.74 | $211.24 | $208.4701 | $210.82 | 1.57M |
| Aug 31, 2026 | $207.24 | $209.84 | $206.01 | $209.05 | 1.22M |
| Aug 28, 2026 | $213.095 | $213.89 | $208.54 | $208.95 | 1.42M |
| Aug 27, 2026 | $213.87 | $215.52 | $213.30 | $214.80 | 1.27M |
| Aug 26, 2026 | $215.43 | $216.07 | $214.03 | $215.23 | 1.39M |
| Aug 25, 2026 | $213.40 | $217.12 | $213.22 | $216.40 | 1.47M |
| Aug 24, 2026 | $212.695 | $213.46 | $210.09 | $212.53 | 1.24M |
| Aug 21, 2026 | $211.55 | $215.605 | $211.06 | $213.56 | 2.68M |
| Aug 20, 2026 | $213.13 | $214.335 | $210.31 | $210.83 | 2.79M |
| Aug 19, 2026 | $210.395 | $217.06 | $209.77 | $216.96 | 2.4M |
| Aug 18, 2026 | $201.93 | $204.07 | $201.29 | $203.56 | 1.54M |
| Aug 17, 2026 | $198.29 | $202.00 | $197.985 | $201.93 | 1.1M |
| Aug 14, 2026 | $198.15 | $198.28 | $195.67 | $198.26 | 583.57K |
The latest Smart Investors Daily articles mentioning IBB.
IBB research
Company profile and research snapshot.
The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Consensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 5, 2026
Jason Snipe picked iShares Biotechnology ETF (IBB) and advised to stay long on biotech, Jenny Van Leeuwen Harrington recommended Amcor plc (AMCR) with great earnings and 5.5% yield.
Benzinga · Feb 4, 2026
SeekingAlpha · Jan 29, 2026
Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why PFE stock is a strong buy.
SeekingAlpha · Jan 26, 2026
IBB ETF analysis: hold rating as biotech consolidates near highs. Fair 19x P/E, low EPS growth and weak seasonality shape risk/reward.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IBB.
